Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.82 |
| ▸ | FLT3 | P36888 | 4/20 | 0.82 |
| ▸ | BLK | P51451 | 3/20 | 0.82 |
| ▸ | BTK | Q06187 | 8/20 | 0.76 |
| ▸ | JAK3 | P52333 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15752472 | 0.91 | EGFR (0.82) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL30192805 | 0.90 | EGFR (1.00) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL16680603 | 0.90 | EGFR (1.00) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL15752437 | 0.90 | EGFR (0.83) | EGFRBTKJAK3 | |
| SCHEMBL18294436 | 0.89 | EGFR (0.87) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL30353489 | 0.89 | EGFR (0.87) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL20080201 | 0.89 | EGFR (0.64) | EGFRFLT3BLKBTK | |
| SCHEMBL18294441 | 0.87 | EGFR (0.86) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL29572941 | 0.87 | EGFR (0.86) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL18012024 | 0.86 | EGFR (1.00) | EGFRBTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306095-B2 | Use of pteridinone derivative serving as EGFR inhibitor | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-04-19 | — | — | US | disclosed |
| US-20180148454-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148454-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| EP-3312180-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | East China University Of Science And Technology (CN) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016192609-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | 华东理工大学 | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306095-B2 | Use of pteridinone derivative serving as EGFR inhibitor | EGFR, ERBB2, ERBB3 | EGFR 1/4885FLT3 20/4885BLK 515/4885 |
| US-20180148454-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | EGFR, ERBB2, ERBB3 | EGFR 1/4885FLT3 20/4885BLK 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.